Up next

Autoplay

PI3K Inhibitors for HR+ Metastatic Breast Cancer

3 Views • 07/03/23
Share
Embed
administrator
administrator
Subscribers
0

Panelists Adam M. Brufsky, MD, PhD; José Baselga, MD, PhD; Carlos L. Arteaga, MD; Debu Tripathy, MD; and Denise A. Yardley, MD, discuss the potential for use of PI3K inhibitors buparlisib, alpelisib, and taselisib and their anticipation of data coming in the near future for breast cancer.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay